StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a research report sent to investors on Saturday. The firm issued a sell rating on the medical equipment provider’s stock.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday.
Get Our Latest Report on Aethlon Medical
Aethlon Medical Stock Down 2.8 %
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Further Reading
- Five stocks we like better than Aethlon Medical
- What Are Growth Stocks and Investing in Them
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What to Know About Investing in Penny Stocks
- Applied Materials Market Capitulates: Now is the Time to Buy
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.